Clinical trials: Cognitive
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Cognitive Symptoms
Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment
The investigators hypothesize that continuous active interaction with environments that are demanding to sensory, cognitive, and motor systems, together with imbedded rewards for successful performance, will help improve memory…
- Conditions
- Breast Cancer, Cognitive Symptoms, Memory Disorders
- Trial name
- NCT00387062
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Posit Science Corporation
Major Depressive Disorder, MDD
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Cognitive Impairment
- Trial name
- NCT05657691
- Testing
- Xanamem™
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 167 people
- Sponsor
- Actinogen Medical
Memory Disorders
Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)
The purpose of this study was to explore in a more documented way the relative potential and efficacy of piracetam 9600 and 4800 mg daily.
- Trial name
- NCT00567060
- Testing
- Piracetam
- Volunteers
- 676 people
- Sponsor
- UCB Pharma
Anxiety, Stress
An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits
The Smart Supplement has 20 vitamins and minerals that have strong track records of demonstrating positive health effects, both physiologically and cognitively.
- Conditions
- Anxiety, Stress, Memory Deficits, Cortisol Overproduction
- Trial name
- NCT05523115
- Testing
- Heights Smart Supplement
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Heights
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Paranoid Schizophrenia
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00506077
- Testing
- MK0249
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Hyperactivity Disorder, Healthy
The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD
Forty children with and 40 children without Attention deficit Hyperactivity Disorder (ADHD) receive Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) or placebo via a dietary intervention.
- Trial name
- NCT01554462
- Testing
- Eicosapentaenoic acid / Docosahexaenoic acid
- Where
- Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Cognitive Functioning of Healthy Individuals
Psychometric Properties of IntelliSpace Cognition
This study aims to validate the tests that are on the IntelliSpace Cognition platform and to establish normative data for these tests.
- Trial name
- NCT03801382
- Testing
- IntelliSpace Cognition (ISC), Paper-Pencil Tests
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Opioid-use Disorder
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC)…
- Trial name
- NCT04948307
- Testing
- OXD01 digital therapy, Standard of Care
- Where
- 21 sites in United States
- Volunteers
- 437 people
- Sponsor
- Orexo AB
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi
Chronic Cerebral Ischemia
Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders
An open-label, prospective, observational, multicenter study. The study enrolls adult outpatients with CCI from 8 federal districts of the Russian Federation.
- Trial name
- DIAMANT (NCT04370028)
- Testing
- Divaza
- Volunteers
- 2,583 people
- Sponsor
- Materia Medica Holding
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Pilot, phase II, prospective, open-label, uncontrolled study of plasma exchange with 5% albumin in 10 subjects having a definite, possible, or probable diagnosis of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02479802
- Testing
- Albumin
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Mental Health Wellness 1, Work Related Stress
Mental Balance Study
The proposed design is a randomised, double-blind, controlled, crossover intervention assessing the effects of an active intervention, containing Scutellaria baicalensis and Crataegus, versus placebo, on stress, cognition, sleep…
- Trial name
- NCT05757050
- Testing
- Re-Focus "Verum" Tablets
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- A. Vogel AG
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Alzheimer Disease
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living…
- Trial name
- NCT07571161
- Testing
- Donanemab
- Where
- 30 sites in China
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company